EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends in financial payments from industry to US cancer centers, 2014-2021

Nirjhar Chakraborty, Meredith Brown, Sonia Persaud, Grace Gallagher, Niti U Trivedi, Peter B Bach, Aaron P Mitchell iD

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Nirjhar Chakraborty und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: National Cancer Institute (U.S.), Drug Industry, Research Support as Topic, National Institutes of Health (U.S.). Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Industry payments to US cancer centers are poorly understood.

Methods

US National Cancer Institute (NCI)–designated comprehensive cancer centers were identified (n = 51). Industry payments to NCI–designated comprehensive cancer centers from 2014 to 2021 were obtained from Open Payments and National Institutes of Health (NIH) grant funding from NIH Research Portfolio Online Reporting Tools (RePORT). Given our focus on cancer centers, we measured the subset of industry payments related to cancer drugs specifically and the subset of NIH funding from the NCI.

Results

Despite a pandemic-related decline in 2020-2021, cancer-related industry payments to NCI–designated comprehensive cancer centers increased from $482 million in 2014 to $972 million in 2021. Over the same period, NCI research grant funding increased from $2 481 million to $2 724 million. The large majority of nonresearch payments were royalties and licensing payments.

Conclusion

Industry payments to NCI–designated comprehensive cancer centers increased substantially more than NCI funding in recent years but were also more variable. These trends raise concerns regarding the influence and instability of industry payments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

National Cancer Institute (U.S.)Drug IndustryResearch Support as TopicNational Institutes of Health (U.S.)Cancer Care FacilitiesUnited StatesHumansConflict of InterestAntineoplastic AgentsNeoplasms

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • US Digital Corps, Office of Technology Transformation Services, US General Services Administration, Washington, DC, USA.
  • Delfi Diagnostics, Baltimore, MD, USA.

ORCID-Profile: Aaron P Mitchell

Förderung

  • NCI NIH HHS
  • NCI

Zitieren

APA

Chakraborty, N., Brown, M., Persaud, S., Gallagher, G., Trivedi, N. U., Bach, P. B., & Mitchell, A. P. (2024). Trends in financial payments from industry to US cancer centers, 2014-2021. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae015

Vancouver

Chakraborty N, Brown M, Persaud S, Gallagher G, Trivedi NU, Bach PB, et al. Trends in financial payments from industry to US cancer centers, 2014-2021. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae015

BibTeX
@article{Chakraborty2024,
  author = {Chakraborty, Nirjhar and Brown, Meredith and Persaud, Sonia and Gallagher, Grace and Trivedi, Niti U and Bach, Peter B and Mitchell, Aaron P},
  title = {Trends in financial payments from industry to US cancer centers, 2014-2021},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae015}
}
Kostenlos starten →